
Neuroendocrine/ Endocrine
Neuroendocrine Cancer
10558: A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetum 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors
GI (Gastroenteropancreatic / Pancreatic tumors)
10479: A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors
Prostate Cancer
10487: A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation